North America Topical Skin Treatment Market Size, Share & Trends Analysis Report By Therapeutic Area (Skin Cancer, Eczema, Psoriasis), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
North America Mosquito Repellent Market Growth & Trends
The global North America mosquito repellent market size is expected to reach USD 2.5 billion by 2030, registering a CAGR of 5.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is majorly driven by rising government initiatives for mosquito control, growing health awareness, and affordable cost of repellents.
Various types of mosquito repellent products available in the market include vaporizers, coils, mats, sprays, bands, and candles. Innovative products are being manufactured by major players to expand their reach. With an improvement in standards of living, increasing urbanization, and rising population, demand for mosquito repellents is constantly on the rise, particularly in tropical parts of the region.
In terms of revenue, vaporizer was the largest product segment, accounting for 32.2% of the North America mosquito repellents market in 2023. Rise in demand for environment-friendly products is propelling demand for mosquito repellents based on natural ingredients.
Companies manufacturing mosquito repellents are constantly making efforts to improve quality and effectiveness of their products. They have been carrying out investments in R&D to discover various new raw materials that can be used to produce mosquito repellents.
North America Mosquito Repellent Market Report Highlights
North America Mosquito Repellent Market Growth & Trends
The global North America mosquito repellent market size is expected to reach USD 2.5 billion by 2030, registering a CAGR of 5.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is majorly driven by rising government initiatives for mosquito control, growing health awareness, and affordable cost of repellents.
Various types of mosquito repellent products available in the market include vaporizers, coils, mats, sprays, bands, and candles. Innovative products are being manufactured by major players to expand their reach. With an improvement in standards of living, increasing urbanization, and rising population, demand for mosquito repellents is constantly on the rise, particularly in tropical parts of the region.
In terms of revenue, vaporizer was the largest product segment, accounting for 32.2% of the North America mosquito repellents market in 2023. Rise in demand for environment-friendly products is propelling demand for mosquito repellents based on natural ingredients.
Companies manufacturing mosquito repellents are constantly making efforts to improve quality and effectiveness of their products. They have been carrying out investments in R&D to discover various new raw materials that can be used to produce mosquito repellents.
North America Mosquito Repellent Market Report Highlights
- Vaporizers accounted for the largest market revenue share of 32.2% in 2023, aided by its convenience and effectiveness. Unlike creams and sprays, vaporizers provide continuous protection over a larger area without requiring reapplication, making them ideal for patios, decks, and indoor spaces.
- The cream & oils segment is expected to register the fastest CAGR of 7.7% during the forecast period.
- Supermarkets dominated the market and accounted for a share of 45.1% in 2023. Supermarkets in North America offer a comprehensive range of mosquito repellents, including sprays, creams, wipes, coils, and vaporizers, catering to diverse customer needs, preferences, and budget points.
- The e-commerce segment is projected to grow at the fastest CAGR of 5.2% over the forecast period. The rise of e-commerce has revolutionized the mosquito repellent market, enabling consumers to purchase products online with ease and convenience.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Therapeutic Areas
1.2.2. Distribution Channel
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Therapeutic Areas outlook
2.2.2. Distribution Channel outlook
2.2.3. Regional outlook
2.3. Competitive Insights
CHAPTER 3. NORTH AMERICA TOPICAL SKIN TREATMENT MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. High prevalence of skin diseases
3.2.1.2. Increasing adoption of topical treatments
3.2.1.3. Growing demand for faster and more effective results
3.2.2. Market restraint analysis
3.2.2.1. Skin irritation and allergies caused by topical drugs
3.2.2.2. Preference for alternative modes of drug delivery
3.2.3. Market opportunity analysis
3.2.3.1. Emerging biologic topical treatments for psoriasis
3.2.3.2. Innovative topical therapies for nonmelanoma skin cancer
3.2.3.3. Growth potential in advanced acne treatment solutions
3.3. North America Topical Skin Treatment Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
CHAPTER 4. NORTH AMERICA TOPICAL SKIN TREATMENT MARKET: THERAPEUTIC AREAS ESTIMATES & TREND ANALYSIS
4.1. North America Topical Skin Treatment Market: Therapeutic Areas Dashboard
4.2. North America Topical Skin Treatment Market: Therapeutic Areas Movement Analysis
4.3. North America Topical Skin Treatment Market: By Therapeutic Areas, Revenue (USD million)
4.4. Skin Cancer
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Fluorouracil (5-FU)
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Imiquimod
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Ingenol Mebutate
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.5. Diclofenac Sodium Gel
4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.6. Tirbanibulin Ointment
4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.7. Others
4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Eczema
4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.2. Corticosteroids
4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.3. Calcineurin Inhibitors
4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.4. Crisaborole (Eucrisa)
4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.5. Topical Antimicrobials
4.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.6. Emollients and Moisturizers
4.5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.7. Others
4.5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Psoriasis
4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.2. Corticosteroids
4.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.3. Vitamin D Analogues
4.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.4. Coal Tar
4.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.5. Tazarotene
4.6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.6. Topical Calcineurin Inhibitors
4.6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.7. Combination Therapies
4.6.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.8. Others
4.6.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Other therapeutic areas
4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. NORTH AMERICA TOPICAL SKIN TREATMENT MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
5.1. North America topical skin treatment market: Distribution Channel Dashboard
5.2. North America topical skin treatment market: Distribution Channel Movement Analysis
5.3. North America topical skin treatment market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
5.4. Hospital Pharmacies
5.4.1. Hospital pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Retail Pharmacies
5.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Others
5.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. NORTH AMERICA TOPICAL SKIN TREATMENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY THERAPEUTIC AREAS, AND DISTRIBUTION CHANNEL
6.1. Regional Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.3.3. Mexico
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework/ reimbursement structure
6.3.3.3. Competitive scenario
6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. Key company market share analysis, 2023
7.3.2. Johnson & Johnson Services, Inc.
7.3.2.1. Company overview
7.3.2.2. Financial performance
7.3.2.3. Product benchmarking
7.3.2.4. Strategic initiatives
7.3.3. GSK Plc
7.3.3.1. Company overview
7.3.3.2. Financial performance
7.3.3.3. Product benchmarking
7.3.3.4. Strategic initiatives
7.3.4. Pfizer, Inc.
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Novartis AG
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. LEO Pharma A/S
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. AbbVie, Inc.
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Bausch Health Companies, Inc.
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Galderma
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Sun Pharmaceutical Industries Ltd.
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Therapeutic Areas
1.2.2. Distribution Channel
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Therapeutic Areas outlook
2.2.2. Distribution Channel outlook
2.2.3. Regional outlook
2.3. Competitive Insights
CHAPTER 3. NORTH AMERICA TOPICAL SKIN TREATMENT MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. High prevalence of skin diseases
3.2.1.2. Increasing adoption of topical treatments
3.2.1.3. Growing demand for faster and more effective results
3.2.2. Market restraint analysis
3.2.2.1. Skin irritation and allergies caused by topical drugs
3.2.2.2. Preference for alternative modes of drug delivery
3.2.3. Market opportunity analysis
3.2.3.1. Emerging biologic topical treatments for psoriasis
3.2.3.2. Innovative topical therapies for nonmelanoma skin cancer
3.2.3.3. Growth potential in advanced acne treatment solutions
3.3. North America Topical Skin Treatment Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
CHAPTER 4. NORTH AMERICA TOPICAL SKIN TREATMENT MARKET: THERAPEUTIC AREAS ESTIMATES & TREND ANALYSIS
4.1. North America Topical Skin Treatment Market: Therapeutic Areas Dashboard
4.2. North America Topical Skin Treatment Market: Therapeutic Areas Movement Analysis
4.3. North America Topical Skin Treatment Market: By Therapeutic Areas, Revenue (USD million)
4.4. Skin Cancer
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Fluorouracil (5-FU)
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Imiquimod
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Ingenol Mebutate
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.5. Diclofenac Sodium Gel
4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.6. Tirbanibulin Ointment
4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.7. Others
4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Eczema
4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.2. Corticosteroids
4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.3. Calcineurin Inhibitors
4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.4. Crisaborole (Eucrisa)
4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.5. Topical Antimicrobials
4.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.6. Emollients and Moisturizers
4.5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.7. Others
4.5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Psoriasis
4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.2. Corticosteroids
4.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.3. Vitamin D Analogues
4.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.4. Coal Tar
4.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.5. Tazarotene
4.6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.6. Topical Calcineurin Inhibitors
4.6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.7. Combination Therapies
4.6.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.8. Others
4.6.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Other therapeutic areas
4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. NORTH AMERICA TOPICAL SKIN TREATMENT MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
5.1. North America topical skin treatment market: Distribution Channel Dashboard
5.2. North America topical skin treatment market: Distribution Channel Movement Analysis
5.3. North America topical skin treatment market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
5.4. Hospital Pharmacies
5.4.1. Hospital pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Retail Pharmacies
5.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Others
5.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. NORTH AMERICA TOPICAL SKIN TREATMENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY THERAPEUTIC AREAS, AND DISTRIBUTION CHANNEL
6.1. Regional Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.3.3. Mexico
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework/ reimbursement structure
6.3.3.3. Competitive scenario
6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. Key company market share analysis, 2023
7.3.2. Johnson & Johnson Services, Inc.
7.3.2.1. Company overview
7.3.2.2. Financial performance
7.3.2.3. Product benchmarking
7.3.2.4. Strategic initiatives
7.3.3. GSK Plc
7.3.3.1. Company overview
7.3.3.2. Financial performance
7.3.3.3. Product benchmarking
7.3.3.4. Strategic initiatives
7.3.4. Pfizer, Inc.
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Novartis AG
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. LEO Pharma A/S
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. AbbVie, Inc.
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Bausch Health Companies, Inc.
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Galderma
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Sun Pharmaceutical Industries Ltd.
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
